Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9884044 | EAGLE PHARMS | Treatment using dantrolene |
Jun, 2022
(7 months ago) | |
US8604072 | EAGLE PHARMS | Treatment using dantrolene |
Jul, 2022
(6 months ago) | |
US8110225 | EAGLE PHARMS | Treatment using dantrolene |
Dec, 2022
(a month ago) | |
US8685460 | EAGLE PHARMS | Treatment using dantrolene |
Feb, 2023
(7 days from now) | |
US7758890 | EAGLE PHARMS | Treatment using dantrolene |
Jun, 2025
(2 years from now) |
Market Authorisation Date: 22 July, 2014
Treatment: For use in the treatment of malignant hyperthermia in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high risk.
Dosage: FOR SUSPENSION;INTRAVENOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic